| Literature DB >> 35719327 |
Songqi Wang1, Haiyan Shen2, Qijie Lin1, Jun Huang3, Chunhong Zhang2, Zhicheng Liu2, Minhua Sun2, Jianfeng Zhang2, Ming Liao2, Yugu Li1, Jianmin Zhang1.
Abstract
African Swine Fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious and lethal viral disease of pigs. However, commercial vaccines are not yet available, and neither are drugs to prevent or control ASF. Therefore, rapid, accurate on-site diagnosis is urgently needed for detection during the early stages of ASFV infection. Herein, a cleaved probe-based loop-mediated isothermal amplification (CP-LAMP) detection method was established. Based on the original primer sets, we targeted the ASFV 9GL gene sequence to design a probe harboring a ribonucleotide insertion. Ribonuclease H2 (RNase H2) enzyme activity can only be activated when the probe is perfectly complementary, resulting in hydrolytic release of a quencher moiety, and consequent signal amplification. The method displayed robust sensitivity, with copy number detection as low as 13 copies/µL within 40 min at constant temperature (62°C). Visualization of the fluorescence product was employed using a self-designed 3D-printed visualization function cassette, and the CP-LAMP method achieved specific identification and visual detection of ASFV. Moreover, coupling the dual function cassette and smartphone quantitation makes the CP-LAMP assay first user-friendly, cost-effective, portable, rapid, and accurate point-of-care testing (POCT) platform for ASFV.Entities:
Keywords: African swine fever virus; CP-LAMP; RNase H2; point-of-care testing; rapid detection; smartphone quantitation
Mesh:
Substances:
Year: 2022 PMID: 35719327 PMCID: PMC9204333 DOI: 10.3389/fcimb.2022.884430
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Primers and probe information of the CP-LAMP assay.
| Name | Sequence (5’→3’) |
|---|---|
| F3 | GCCGGTTATTTACGTTGTT |
| B3 | TTTCAGACGCTCCTAGCT |
| FIP | CACGCCTTTTCGTATCTTACAAAAACGAAGGTCCAGTACTGAAAG |
| BIP | CTGGTGCATGGCAGAGACTCAAGAAAAATATGAAGCCATCCA |
| LF | ACATTAAACAACTCGGAGGA |
| probe | FAM-ACATTAAACAACTC |
The bold and underline letter indicates that the base is a ribonucleotide.
Figure 1Schematic diagram of the 9GL gene showing the position and composition of ASFV CP-LAMP primers and probe. F3, forward outer primer (F3); B3, backward outer primer; FIP (F1c+F2), forward inner primer; BIP (B1+B2c), backward inner primer; LF, loop forward primer; Probe, cleaved probe.
Figure 2Basic reaction system was performed in real-time PCR instrument (A) and the results were observed using 3D-printed visualization function cassette (B). (a) ASFV standard plasmid (in triplicate test). (b) Negative control.
Figure 3Temperature optimization results. (A) 61°CC. (B) 60°CC, (C) 62°CC, (D) 64°CC, (E) 63°CC.
Specificity of the CP-LAMP assay.
| Pathogen | ASFV | PRV | PCV2 | PPV | CSFV | PRRSV | PEDV | TGEV |
|---|---|---|---|---|---|---|---|---|
| Result | + | – | – | – | – | – | – | – |
Figure 4Specificity analysis was performed in real-time PCR instrument (A) and observed by the 3D-printed visualization function cassette (B). (a) ASFV. (b) PRV. (c) PCV2. (d) CSFV. (e) PRRSV. (f) PPV. (g) PEDV. (h) TGEV. (i) Negative control.
Figure 5Detection limit analysis used the real-time PCR instrument (A) and observed by the 3D-printed visualization function cassette (B). CP-LAMP was used tested using ASFV plasmid diluted to various concentrations. (a) 1.3×106 copies/µL. (b) 1.3×105 copies/µL. (c) 1.3×104 copies/µL. (d) 1.3×103 copies/µL. (e) 1.3×102 copies/µL. (f) 1.3×101 copies/µL. (g) 1.3×100 copies/µL. (h) Negative control.
Reproducibility of the CP-LAMP method.
| Plasmid concentration(copies/μL) | Intra-assay coefficient of variation | Inter-assay coefficientof variation |
|---|---|---|
| 1.3×106 | 3.01% | 1.98% |
| 1.3×105 | 1.96% | 0.11% |
| 1.3×104 | 4.20% | 0.83% |
| 1.3×103 | 3.41% | 1.87% |
| 1.3×102 | 4.54% | 0.58% |
Detection of suspected clinical ASFV samples.
| Number of Samples | Traditional PCR | CP-LAMP | TaqMan probe real-time PCR | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| 61 | 13 | 48 | 17 | 44 | 17 | 44 |
Figure 6Partial visualization results of clinical samples using the 3D-printed visualization function cassette: +, Positive control; -, Negative control; (a–f) are clinical samples.